Danielle Brandman, MD

Hepatologist

Dr. Danielle Brandman is a liver specialist, or hepatologist, who has expertise in treating patients with nonalcoholic fatty liver disease and patients needing liver transplants. She also treats conditions such as cirrhosis, primary biliary cirrhosis, liver cancer, autoimmune hepatitis, hepatitis B and primary sclerosing cholangitis. In her research, she studies nonalcoholic fatty liver disease and post-transplant metabolic syndrome.

Brandman earned a medical degree at the New Jersey Medical School of the University of Medicine and Dentistry of New Jersey in Newark, and completed an internal medicine internship and residency at UCSF. She also completed fellowships in gastroenterology and transplant hepatology and earned a master's of advanced studies in clinical research at UCSF. Brandman is certified by the American Board of Internal Medicine in internal medicine, gastroenterology and transplant hepatology, and is a member of the American Association for the Study of Liver Disease (AASLD). She is an assistant professor of medicine at UCSF.

Clinics

Liver Disease and Liver Transplant
350 Parnassus Ave., Suite 300
San Francisco, CA 94143
Phone: (415) 353-2318
Fax: (415) 353-2407

Hours: Monday to Friday
8:30 a.m. – 4:30 p.m.

Polycystic Kidney Disease (PKD) Center of Excellence
400 Parnassus Ave., B1 Plaza Level
San Francisco, CA 94143
Phone: (415) 514-2381

Hours: Monday to Friday,
9 a.m. - 5 p.m.

Board Certification

Gastroenterology, American Board of Internal Medicine
Internal Medicine, American Board of Internal Medicine
Transplant Hepatology, American Board of Internal Medicine

Academic Title

Assistant Professor

More about Danielle Brandman

Education

University of Medicine and Dentistry of New Jersey, New Jersey Medical School 2005

Residencies

UCSF Medical Center, Internal Medicine 2008

Fellowships

UCSF Medical Center, Gastroenterology 2011
UCSF Medical Center, Transplant Hepatology 2012

Selected Research and Publications

  1. Kushner T, Shinkai K, Fox L, Ying D, Gross A, Balitzer D, Gill R, Brandman D. New presentation of autoimmune hepatitis with erythema multiforme. Hepatology. 2018 Apr; 67(4):1628-1630.
  2. Vuppalanchi R, Siddiqui MS, Van Natta ML, Hallinan E, Brandman D, Kowdley K, Neuschwander-Tetri BA, Loomba R, Dasarathy S, Abdelmalek M, Doo E, Tonascia JA, Kleiner DE, Sanyal AJ, Chalasani N. Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease. Hepatology. 2018 01; 67(1):134-144.
  3. Kardashian AA, Dodge JL, Roberts J, Brandman D. Weighing the risks: Morbid obesity and diabetes are associated with increased risk of death on the liver transplant waiting list. Liver Int. 2018 Mar; 38(3):553-563.
  4. Lewin SM, Mehta N, Kelley RK, Roberts JP, Yao FY, Brandman D. Liver transplantation recipients with nonalcoholic steatohepatitis have lower risk hepatocellular carcinoma. Liver Transpl. 2017 Aug; 23(8):1015-1022.
  5. Dakson A, Brandman D, Thibault-Halman G, Christie SD. Optimization of the mean arterial pressure and timing of surgical decompression in traumatic spinal cord injury: a retrospective study. Spinal Cord. 2017 Nov; 55(11):1033-1038.
  6. Brandman D. Editorial: are earlier referrals to transplant centres responsible for improved outcomes in patients with acute liver failure? Aliment Pharmacol Ther. 2017 05; 45(9):1272-1273.
  7. Brandman D, Bacchetti P, Ayala CE, Maher JJ, Khalili M. Impact of insulin resistance on HCV treatment response and impact of HCV treatment on insulin sensitivity using direct measurements of insulin action. Diabetes Care. 2012 May; 35(5):1090-4.
  8. Brandman D, Pingitore A, Lai JC, Roberts JP, Ferrell L, Bass NM, Terrault NA. Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent hepatitis C virus. Liver Transpl. 2011 Dec; 17(12):1380-6.
  9. Brandman D, Biggins SW, Hameed B, Roberts JP, Terrault NA. Pretransplant severe hepatic encephalopathy, peritransplant sodium and post-liver transplantation morbidity and mortality. Liver Int. 2012 Jan; 32(1):158-64.
  10. Canuso CM, Goldstein JM, Wojcik J, Dawson R, Brandman D, Klibanski A, Schildkraut JJ, Green AI. Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Psychiatry Res. 2002 Aug 05; 111(1):11-20.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.